Tilray Bets on Cannabis Demand to Reverse Revenue Slide

Revenue Mix Shifts as Canadian Cannabis Stagnates

Tilray's cannabis segment generated $54 million in revenue during its most recent quarter, down 12% year-over-year, according to the company's Q4 2026 earnings filed with the SEC. The decline reflects continued oversupply in Canada, where gram prices have fallen below $3 CAD at wholesale in some provinces. Beverage alcohol and wellness products now account for 62% of total revenue, up from 48% a year ago.

The company operates 17 cultivation facilities across Canada and Europe. Four Canadian grow sites have been idled since January 2026 to align capacity with demand.

U.S. Rescheduling Timeline Drives Bull Case

The bull case hinges on federal cannabis rescheduling in the United States. If the DEA finalizes its proposed move of cannabis from Schedule I to Schedule III, Tilray's U.S.-based CBD and hemp brands could expand into THC product lines without violating federal law. Distribution agreements with 14,000 U.S. retail doors already support its non-intoxicating wellness products.

Canaccord Genuity analysts estimate Tilray could deploy $200 million in M&A capital toward U.S. cannabis assets within 90 days of federal rescheduling. The firm maintains a speculative buy rating with a $2.75 price target, implying 38% upside from the August 9 close of $1.99.

Debt Covenants Tighten as EBITDA Margins Compress

Tilray carries $387 million in senior secured debt with a leverage covenant capped at 4.5x net debt to adjusted EBITDA. The company reported 4.1x leverage in its May quarter. That leaves limited cushion if EBITDA deteriorates further. Adjusted EBITDA margin compressed to 8.2% from 11.4% a year earlier, driven by promotional spending in beverage alcohol and higher logistics costs in Europe.

Comparable-Company Multiples Show Discount

Tilray trades at 0.4x trailing revenue, a 60% discount to the peer median of 1.0x for diversified cannabis operators. Canopy Growth (NASDAQ:CGC) trades at 0.8x revenue despite similar Canadian exposure. Investors worry about Tilray's cash-burn trajectory and the uncertain timing of U.S. federal reform.

Management Signals M&A Appetite in Craft Beer

CEO Irwin Simon said on the August 8 earnings call that Tilray is evaluating craft beer acquisitions in the U.S. and Europe to scale its beverage platform. The company's acquired eight beer and spirits brands since 2021, including SweetWater Brewing and Montauk Brewing. Beverage gross margins of 42% exceed cannabis margins of 28%. That makes the segment a priority for capital allocation.

What to Watch

The next catalyst is the DEA's final rescheduling decision, expected by December 2026. Investors will also watch Tilray's Q1 fiscal 2027 results in October for signs of stabilization in Canadian cannabis revenue. For full background on Tilray's capital structure and competitive positioning, see the CannIntel topic hub on Tilray Brands stock analysis.